

LIFE SAVING DRUGS PROGRAM EXPERT PANEL SEVENTH MEETING: 22-23 October 2020

AGENDA

1. Standing business

- 1.1. Welcome & apologies
- 1.2. Declaration of potential or actual Conflict of Interest
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2. Reviews of existing LSDP medicines

TRANCHE 1 – finalise outcomes of reports

- 2.1 Agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for treatment of Fabry disease
- 2.2 Imiglucerase (Cerezyme®), velaglucerase (VPRIV®) and taliglucerase (Elelyso®) for treatment of Gaucher disease

TRANCHE 2 – finalise outcomes of reports

- 2.3 Eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria
- 2.4 Idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis Type II
- 2.5 Alglucosidase alfa (Myozyme®) for treatment of Pompe disease

TRANCHE 3 – review of final reports

- 3.1 Laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
- 3.2 Galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
- 3.3 Nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

3. Applications for new LSDP medicines

4. Other business